Price
Target price
€0.38
€0.38
2.150%
0.008
2.150%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Thiogenesis Therapeutics Corp. Stock
There is an upward development for Thiogenesis Therapeutics Corp. compared to yesterday, with an increase of €0.008 (2.150%).
Pros and Cons of Thiogenesis Therapeutics Corp. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
C******** o* t** e**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
News
Thiogenesis Reports Positive Interim Phase 2 Trial Results for MELAS and Announces Pipeline Advancements in Leigh Syndrome and Cystinosis
Trial achieved biological proof-of-concept, dose discovery and biomarker improvement
San Diego, California, November 4, 2025 – Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF)
Thiogenesis Receives Confirmatory Guidance on IMPD for Pediatric MASH Phase 2a Clinical Trial in Europe and Core Patent Granted in EU
San Diego, CA, June 25, 2025 – Thiogenesis Therapeutics, Inc. (TSXV: TTI | OTCQX: TTIPF), a clinical-stage biopharmaceutical company developing next-generation thiol-based therapies for
Thiogenesis Announces Second Site Begins Enrolling in Phase 2 MELAS Clinical Trial and Provides Update
San Diego, California, June 17, 2025 – Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) (“Thiogenesis” or the “Company”) a clinical-stage biopharmaceutical company developing